Phase 2a: Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.Clinical trial number: NCT00628095;. The gene discussed is P2RX7; the disease is rheumatoid arthritis.